Researchers at the Swiss Federal Institute of Technology in Lausanne (EPFL) have unveiled a pill‑sized device that deposits living “bio‑ink” directly onto injured tissue inside the gastrointestinal (GI) tract, demonstrating navigation and controlled ink release in lab models and live rabbits. The preclinical work, published in Advanced Science and described by EPFL on October 16, 2025, presents the Magnetic Endoluminal Deposition System (MEDS) as an ingestible, magnet‑guided bioprinter designed for minimally invasive repair of ulcers and other soft‑tissue defects in the gut. According to the study, the capsule operates without onboard electronics, uses near‑infrared light to trigger bio‑ink extrusion, and can be steered and retrieved with external magnets under fluoroscopic guidance. Advanced Science, EPFL
What the study showed
In benchtop tests, the EPFL team guided MEDS to deposit bio‑ink over artificial gastric ulcers and to seal a simulated hemorrhage on tissue models. In a rabbit feasibility study, investigators navigated the capsule within the stomach and delivered patterned deposits under real‑time X‑ray fluoroscopy. The authors emphasize that the work establishes core engineering principles and feasibility only; it does not demonstrate clinical efficacy for healing human ulcers or controlling GI bleeding. Advanced Science, EPFL
How the device works
MEDS is roughly the size of a large capsule. It houses a chamber of bio‑ink and a spring‑plunger that releases material when activated by near‑infrared (NIR) light delivered from outside the body. NIR wavelengths are widely used in biomedicine because they can penetrate soft tissues more effectively than visible light, enabling remote triggering in certain applications. Theranostics (systematic review)
During operation, an external robotic arm holding a magnet steers the capsule along the mucosal surface to lay down continuous lines or patches of bio‑ink—an approach intended to provide the tissue contact that bioprinting requires. The team reports that the capsule can be re‑captured magnetically. EPFL, Advanced Science
Context: what patients receive today
Peptic ulcers and many causes of upper GI bleeding are typically treated without surgery. Standard care involves medications—such as proton pump inhibitors and, when indicated, antibiotics to eradicate Helicobacter pylori—and therapeutic endoscopy to achieve hemostasis or close ulcers at high risk of rebleeding. The American College of Gastroenterology recommends endoscopic therapy (thermal devices, injection, clips, hemostatic powders, and over‑the‑scope clips for recurrence) and high‑dose proton pump inhibitors after successful hemostasis. Surgery or transcatheter embolization is reserved for cases that fail endoscopic management. American Journal of Gastroenterology guideline, NIDDK treatment overview
Why this matters: If future clinical studies validate the approach, an ingestible bioprinter could complement—not replace—endoscopic therapies by offering a non‑surgical option when endoscopy is unavailable or technically challenging.
How MEDS compares with current “smart capsules”
Commercial capsule endoscopy provides imaging of the GI tract but generally does not perform therapy. Research groups have demonstrated magnetically controlled capsules for enhanced imaging and experimental interventions, and meta‑analyses report acceptable diagnostic performance for magnetically controlled capsule gastroscopy compared with conventional endoscopy. However, controlled contact with tissue for tasks like printing remains an engineering challenge for untethered devices. MEDS specifically targets surface contact and patterned deposition. Gastrointestinal Endoscopy (systematic review), Prospective comparative trial, Experimental magnetic biopsy capsule
What’s in the “bio‑ink”
EPFL describes using a living bio‑gel that can carry cells or drugs. Many bio‑inks for soft‑tissue applications are based on alginate, a polysaccharide derived from brown seaweed, often combined with other polymers to tune mechanical and biological properties. Alginate‑based inks are widely studied for biocompatibility and rapid gelation, though long‑term degradation and cell adhesion require careful formulation. These characteristics are relevant if bio‑inks are expected to protect ulcers from acid and act as micro‑bioreactors that release growth factors. Review of alginate bio‑inks, Journal of Materials Chemistry B review
Safety and feasibility questions
As with all ingestible devices, key risks include capsule retention, aspiration, and mucosal injury. Large series of video capsule endoscopy report retention rates around 1%–2% overall—higher in patients with Crohn’s disease or strictures—and strategies such as patency capsules and cross‑sectional imaging reduce this risk. MEDS will need human data to characterize retention risk, magnetic retrieval reliability, and compatibility with existing endoscopic/emergency workflows if retrieval fails. Systematic review of capsule retention, Diagnostics review
NIR triggering is attractive for remote control but requires dose limits and careful thermal management, particularly in inflamed or ischemic tissue. NIR devices are used across imaging and phototherapies because of favorable tissue optics, yet penetration and safety vary by wavelength, power, exposure time, and tissue type—parameters that would need clinical validation for an ingestible system. Theranostics (systematic review)
Potential public‑health impact
Therapeutic endoscopy is highly effective but unevenly available worldwide. Surveys in Eastern Africa, for example, have documented critically low capacity—approximately 0.12 endoscopists and 0.12 gastroscopes per 100,000 people—with cost and equipment shortages as major barriers. If proven safe and effective in humans, a magnet‑guided, low‑infrastructure device could, in principle, expand options where endoscopic resources are scarce. That promise must be weighed against real‑world needs for imaging, guidance, retrieval, sterilization, and supply chains. Endoscopy International Open (capacity study)
What comes next
The EPFL team reports plans to extend MEDS to other hollow organs and surfaces, such as blood vessels and the peritoneum. Before any patient use, the technology will require rigorous biocompatibility testing of inks, chronic retention and motility studies, device‑tissue interaction assessments in active bleeding, and human trials under regulatory oversight. For now, MEDS should be seen as an engineering advance that complements active efforts to make GI care less invasive, alongside guideline‑supported endoscopic therapies that remain the standard of care. EPFL, American Journal of Gastroenterology guideline
For background on innovations that could change how clinicians diagnose and treat disease, read more on Globally Pulse Health.
